Abstracts tagged "Corticosteroids and rheumatoid arthritis"

Abstract Number: 2481 • 2012 ACR/ARHP Annual Meeting
Time Trends in Corticosteroid Use in Rheumatoid Arthritis: Results From a Population Based Inception Cohort 1980–1994 Vs. 1995–2007
Ashima Makol¹, John M. Davis III², Cynthia S. Crowson³, Terry M. Therneau³, Sherine E. Gabriel⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Corticosteroids (CS) are a double edged sword in rheumatoid arthritis (RA) treatment. Low doses may have disease modifying effects but long-term use risks detrimental…
Abstract Number: 452 • 2012 ACR/ARHP Annual Meeting
Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose
Daniele F. Pereira¹, Rita N.V. Furtado², Natalia P. Machado³ and Jamil Natour⁴, ¹Disciplina de Reumatologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Disciplina de Reumatologia, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The optimal dose of corticosteroid to be used in intraarticular injection is not well established. The objective of this study is to compare the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].